Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03842228
Title Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Copanlisib + Durvalumab + Olaparib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Hospital Suspended Aurora Colorado 80045 United States Details
Brigham and Women's Hospital Recruiting Boston Massachusetts 02115 United States Details
Beth Israel Deaconess Medical Center Suspended Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
University of Texas at Austin Recruiting Austin Texas 78712 United States Details
University of Texas Medical Branch Recruiting Galveston Texas 77555-0565 United States Details
M D Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
University of Texas Health Science Center at San Antonio Suspended San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field